Amicus Therapeutics, Inc.  

(Public, NASDAQ:FOLD)   Watch this stock  
Find more results for FOLD
10.44
+0.35 (3.47%)
Jun 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.93 - 10.48
52 week 4.41 - 10.48
Open 10.12
Vol / Avg. 2.92M/3.19M
Mkt cap 1.51B
P/E     -
Div/yield     -
EPS -1.52
Shares 142.92M
Beta 1.84
Inst. own 121%
Aug 7, 2017
Q2 2017 Amicus Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 15, 2017
Amicus Therapeutics Inc at Goldman Sachs Global Healthcare Conference - Webcast
Jun 13, 2017
Amicus Therapeutics Inc Annual Shareholders Meeting
Jun 9, 2017
Amicus Therapeutics Inc Annual Shareholders Meeting (Estimated)
May 22, 2017
Amicus Therapeutics Inc at UBS Global Healthcare Conference - Webcast
May 17, 2017
Amicus Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 15, 2017
Amicus Therapeutics Inc Conference Call To Update on Positive Functional Data from Initial Patients in Pompe Phase 1/2 study - Webcast
May 9, 2017
Q1 2017 Amicus Therapeutics Inc Earnings Release
May 9, 2017
Q1 2017 Amicus Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -1319.07% -4034.73%
Operating margin -1247.66% -3936.91%
EBITD margin - -3601.84%
Return on average assets -21.73% -20.57%
Return on average equity -65.75% -56.51%
Employees 263 -
CDP Score - -

Address

1 Cedarbrook Dr
CRANBURY, NJ 08512-3618
United States - Map
+1-609-6622000 (Phone)
+1-609-6622001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency.

Officers and directors

John F. Crowley J.D. Chairman of the Board, Chief Executive Officer
Age: 50
Bio & Compensation  - Reuters
Bradley L. Campbell President, Chief Operating Officer
Age: 41
Bio & Compensation  - Reuters
William D. Baird III Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Daphne E. Quimi Senior Vice President - Finance and Administration, Corporate Controller
Age: 51
Bio & Compensation  - Reuters
Kurt J. W. Andrews Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
Hung Viet Do Chief Scientific Officer
Age: 49
Bio & Compensation  - Reuters
Ellen S. Rosenberg General Counsel and Corporate Secretary
Age: 54
Bio & Compensation  - Reuters
Jay A. Barth M.D. Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
Donald J. Hayden Jr. Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Robert A. Essner Independent Director
Age: 70
Bio & Compensation  - Reuters